MSN Pharmaceuticals

What MSN Pharmaceuticals does

MSN Pharmaceuticals Inc. (MSNPI) is a privately-held, US-domiciled generic pharmaceutical development and manufacturing company established in 2014 as a wholly-owned subsidiary of the India-based MSN Group of Companies. It operates a single 225,000 sq ft finished dosage manufacturing facility on 15 acres in Piscataway, New Jersey, built in 2018 and equipped with Glatt, Fette, Korsch, and Bosch systems. The facility manufactures immediate release, delayed release, and extended release tablets and capsules, powder/liquid-in-capsule, oral and topical solutions, oral suspensions, and DEA-controlled substances via vault/cage infrastructure with HEPA filtration and cross-contamination-controlled HVAC.

The company's product portfolio spans more than 300 Active Pharmaceutical Ingredients (APIs) and over 200 finished dosage formulations across multiple therapeutic categories, supported by 350+ national and international patents. MSNPI serves two customer sets: internal MSN Group entities (including MSN Laboratories) and external clients through Contract Development and Manufacturing Organization (CDMO) services. Its most prominent recent commercial move is Semabest, a generic semaglutide pre-filled pen launched in India in April 2026 at roughly half the innovator drug's price following CDSCO approval, signaling a step into complex peptide generics. Group-level distribution reaches the USA, UK, Mexico, Colombia, Kazakhstan, Nigeria, Kenya, and Vietnam.

Name

MSN Pharmaceuticals

Legal name

MSN Pharmaceuticals Inc.

Website

https://msnpi.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Generic pharmaceutical manufacturing
• Contract development manufacturing
• Active pharmaceutical ingredients
• Finished dosage formulations
• Controlled substance manufacturing

Headquarters

HQ city

Piscataway

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Product Sales: Development and manufacturing of generic pharmaceutical products for MSN group and external customers. Portfolio includes over 300 APIs and 200+ product formulations across multiple therapeutic categories.
2. Contract Development and Manufacturing Services (CDMO): Contract development and manufacturing organization providing pharmaceutical product development and manufacturing services to global markets with backward integrated APIs.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

MSNPI develops and manufactures high-quality generic pharmaceutical finished dosage forms, including immediate release, delayed release, and extended release tablets and capsules, oral and topical solutions, suspensions, and DEA-controlled substances. The company offers contract development and manufacturing (CDMO) services backed by a portfolio of 300+ Active Pharmaceutical Ingredients and 200+ product formulations, serving both the parent MSN Group and external global pharmaceutical clients.

Product overview

MSN Pharmaceuticals Inc. (MSNPI) is a pharmaceutical generic development and manufacturing company operating as a fully owned subsidiary of the MSN Group of Companies. The company operates a state-of-the-art finished dosage manufacturing facility in Piscataway, New Jersey, established in 2014 with the finished dosage facility built in 2018. Their portfolio includes over 300 Active Pharmaceutical Ingredients (APIs) and over 200 product formulations across multiple therapeutic categories. The core product offerings consist of generic pharmaceutical finished dosage forms including immediate release tablets/capsules, delayed release and extended release formulations, oral solutions, suspensions, and controlled substances. MSNPI also provides backward-integrated contract development and manufacturing services to global markets. Recent product launches include Semabest, a generic semaglutide pre-filled pen launched in April 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Pharmaceutical Finished Dosage Products Generic finished dosage pharmaceutical products including immediate release tablets and capsules, delayed release and extended release tablets and capsules, powder and liquid in hard gelatine capsules, oral and topical solutions, oral suspensions, powder for oral suspensions, and DEA controlled substances, manufactured for the MSN Group and external clients.
• Semabest (Generic Semaglutide) Generic version of semaglutide launched in the Indian market following CDSCO approval, available as a pre-filled pen for subcutaneous administration and priced approximately 50% lower than the innovator drug.
• Active Pharmaceutical Ingredients (APIs) Portfolio of over 300 Active Pharmaceutical Ingredients across multiple therapeutic categories, providing backward integration for MSNPI's formulation business and CDMO services.
• Contract Development and Manufacturing Services (CDMO) Contract development and manufacturing services for complex pharmaceutical products with backward-integrated APIs, delivered to global pharmaceutical clients from MSNPI's Piscataway, New Jersey facility.

Quantifiable outcome

• Generic semaglutide (Semabest) launched at approximately 50% lower cost than innovator drug

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered core.

• GlattcoreTechnology or IntegrationEquipment vendor for pharmaceutical manufacturing. MSNPI utilizes Glatt equipment as part of their state-of-the-art finished dosage manufacturing facility equipment mix.
• FettecoreTechnology or IntegrationEquipment vendor for tablet press and manufacturing equipment. Fette equipment installed as part of MSNPI's advanced pharmaceutical manufacturing infrastructure.
• KorschcoreTechnology or IntegrationEquipment vendor for pharmaceutical tablet press machinery. Korsch equipment provides high-speed tablet compression capabilities at MSNPI facility.
• BoschcoreTechnology or IntegrationEquipment vendor for pharmaceutical manufacturing including packaging and processing equipment. Bosch systems integrated into MSNPI's manufacturing operations.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Zydus Lifesciences (Cadila Healthcare): Indian generic manufacturer with integrated APIs, US finished-dose facilities, and a broad specialty/generic portfolio overlapping with MSNPI's formulation breadth.
• Aurobindo Pharma: Vertically integrated Indian generic manufacturer with significant US finished-dose operations and APIs across many of the same therapeutic categories as MSNPI; competes head-to-head for ANDAs and CDMO contracts.
• Dr. Reddy's Laboratories: Indian-headquartered generic pharmaceutical company with a large US generics business, integrated API manufacturing, and CDMO services — directly comparable in scope and customer base to MSNPI.
• Lupin Pharmaceuticals: Indian generic pharma major with US finished-dose manufacturing, complex generics, and controlled-substance capabilities, competing for similar hospital and retail accounts as MSNPI.
• Apotex: Large Canadian-headquartered generic manufacturer with vertically integrated APIs and US finished-dose operations, competing in many of the same molecule categories as MSNPI.
• Glenmark Pharmaceuticals: India-based generic and specialty pharma company with US generics, complex formulations, and backward API integration analogous to MSNPI's operating model.
• Alkem Laboratories: Indian generic pharmaceutical company with US operations, integrated API/finished-dose manufacturing, and a formulation portfolio spanning similar therapeutic categories as MSNPI.

Broad incumbents

• Sandoz (Novartis): Global generics and biosimilars major carved out of Novartis with integrated API manufacturing and US/EU finished-dose facilities; competes with MSNPI across most generic molecules.
• Endo International: US-based specialty generics and branded pharma company with significant sterile injectable and complex generic capabilities, including controlled substances — directly overlapping with MSNPI's complex-generic focus.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a US manufacturing footprint, broad API capabilities, and controlled-substance franchises; serves as a benchmark incumbent against which MSNPI competes for share.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MSN Pharmaceuticals